GKSL Monitoring Agency Report: Funds Utilized as per SEBI Norms for Q4FY26
Gujarat Kidney and Super Speciality Limited's Q4FY26 Monitoring Agency Report confirms utilization of ₹250.80 Crore IPO funds. No deviations from objects were noted. Funds were used for acquisitions, capital expenditure, and debt repayment. Unutilized funds remain in bank accounts and fixed deposits.
This is a standard regulatory compliance report detailing past fund utilization. It does not introduce new material information that would significantly impact the company's stock or market valuation.
The report is a routine monitoring agency submission confirming compliance with fund utilization as per SEBI regulations. It does not contain new financial performance data or significant operational updates that would influence sentiment.
Gujarat Kidney and Super Speciality Limited (GKSL) has submitted its Third Monitoring Agency Report for the quarter ended June 30, 2026. This report, prepared by Brickwork Ratings (BWR), details the utilization of funds raised through a Fresh Issue of Equity Shares amounting to ₹250.80 Crore.
According to the report, there have been no deviations from the stated objects of the issue. The company has utilized funds for various purposes including the proposed acquisition of Parekhs Hospital at Ahmedabad (₹77.00 Crore), part-payment for the acquired "Ashwini Medical Centre" (₹12.40 Crore), and acquisition of additional shareholding in its subsidiary "Harmony Medicare Private Limited" (₹10.78 Crore). Capital expenditure for a new hospital in Vadodara was funded with ₹4.95 Crore, and ₹1.20 Crore was used for repayment of outstanding secured borrowings. Additionally, ₹74.82 Crore was allocated for inorganic growth and general corporate purposes, while ₹6.83 Crore was utilized for setting up dialysis services in collaboration with Lord’s Mark Industries Limited. The report also indicates that ₹17.92 Crore is allocated for healthcare expansion, ₹7.23 Crore for acquiring a stake in Blue Tree Clinics LLC, Dubai, and ₹24.63 Crore for issue expenses.
The report confirms that all utilization is as per the disclosures in the Offer Document, and necessary shareholder approvals have been obtained for any material deviations. The company has also completed several objects as per the Offer Document, including acquisitions and capital expenditure. The unutilized proceeds as of June 30, 2026, are primarily held in HDFC Bank accounts and fixed deposits.
What to do with a filing like this
Gujarat Kidney And Super Speciality Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gujarat Kidney And Super Speciality Limited. Read the original for the full detail.